MCOSA Home Page MCOSA Home Page MCOSA Home Page MCOSA Home Page MCOSA Home Page MCOSA Home Page MCOSA Home Page MCOSA Home Page MCOSA Home Page Home Page Contact MCOSA Meet MCOSA
 Substance Abuse

Hepatitis C: An Overview

Prevalence | Incidence | Demographics | Natural History | Transmission
Prevention | HCV Testing | Treatment | What You Need To Know

HCV Testing

Who should be tested?

  • Testing Routinely Recommended Based on Risk of Infection
  • Person who ever injected illegal drugs
  • Persons with selected medical conditions
    • Persons who received clotting factor concentrates produced before 1987
    • Persons who were ever on long-term hemodialysis
    • Persons with persistently abnormal alanine aminotransferace levels (persons with chronic liver disease)
  • Testing Routinely Recommended Based on Risk of Infection
  • Prior recipients of transfusions or solid organs
    • Persons who were notified that they received blood from a donor who later tested positive for HCV infection
    • Persons who received a transfusion of blood or blood components before July 1992
    • Persons who received an organ transplant before July 1992
  • Testing Routinely Recommended Based on Need for Exposure
    • Health care, emergency medical, and public safety workers after needlesticks, sharps, or mucosal exposures to HCV positive blood
    • Children born to HCV positive women

What do test results mean?

  • Initial Screening
    • Used to determine exposure/detect hepatitis C antibodies.
    • Example: Enzyme immunoassays (EIA)
    • It takes an average of 6 to 8 weeks before antibodies can be detected.
    • Within three months of infection, 97 percent of persons will have sufficient antibodies to be detected with a screening test.
  • Initial Screening – Negative Result
    • A negative test most likely means that a person is not infected.
    • False negatives are uncommon.
      • May occur if a person has been recently infected.
      • May occur in individuals who are immuno-suppressed or on long-term hemodialysis.
  • Initial Screening - Positive Result
    • False positives are uncommon.
      • Most likely to occur in individuals at low-risk for infection.
      • May occur in individuals with autoimmune liver disease.
    • A positive test, especially in a person with known risk factors, most likely means that they have been exposed to the virus.
    • Screening test results can be verified with a supplemental or confirmatory test.
  • Confirmatory Testing
    • To ensure that a positive screening test result is a true positive.
    • To distinguish between a resolved and an active infection.
    • They can be used alone or more than one test can be used.
  • Supplemental Confirmatory Assay
    • Detects antibodies to HCV.
    • Recombinant immunoblot assay (RIBA)
    • Can be done on the same blood sample as the screening assay.
    • Used to determine whether an antibody positive result is a true positive result, especially in low prevalence populations.
  • Virus Detection Tests
    • Nucleic Acid Tests (NATs)
    • Tests that determine presence of the hepatitis C virus in the blood through detection of HCV RNA.
    • Detection of HCV RNA provides definitive proof that an infection exists.
    • There are both qualitative and quantitative virus detection tests.
  • Qualitative Virus Detection Tests
    • Can detect the virus as early as one or two weeks after exposure.
    • Can detect the virus at lower levels than quantitative tests.
    • Are the preferred test for determining active infection. (AMA guidelines)
    • Examples: Reverse Transcriptase-polymerase chain reaction assays (RT-PCR) or Transcription mediated amplification (TMA)
  • Quantitative Virus Detection Tests
    • Can quantify the actual amount of the virus or the viral load.
    • Often used to monitor response to treatment.
    • Examples: Reverse Transcriptase-polymerase chain reaction assays (RT-PCR), Transcription mediated amplification (TMA), or branched chain DNA assays
  • AMA: Testing Asymptomatic People Flowchart
  • S/Co Ratios
    • The CDC guidelines allow for the use of screening-test-positive signal-to-cut off ratios (s/co ratios) to determine need for supplemental testing.
    • Positive screening tests with high s/co ratios have been demonstrated to predict a supplemental serologic-test-positive 95 percent or greater of the time.
    • These tests can be reported as HCV-antibody positive without supplemental testing.
  • S/Co-Ratios - MDCH Flowchart

If a person is chronically infected what other tests will they do?

  • Genotyping
    • There are at least six different genotypes of HCV.
      • Genotype 1 - 70 to 75 percent of persons infected in the US.
      • Genotypes 2 and 3 – 10 to 15 percent of persons infected in the US.
    • Genotype testing should be done on all HCV positive people considering treatment.
      • Often determines length of treatment.
      • Is also a predictor of response to treatment.
  • Liver Enzyme Tests
    • Elevated ALT levels are an indirect measure of liver cell inflammation and damage.
    • In patients with risk factors and elevated liver enzymes, HCV infection is probable.
    • However, the absence of elevation does not rule out significant liver damage.
    • One-third to one-half of HCV infected individuals will have a normal ALT level.
  • Liver Biopsy
    • Most sensitive measure of disease severity.
    • Used to determine stage of fibrosis.
    • Can be used to help predict natural history of disease.
    • Often used to determine the need for treatment.
    • Can also be used to predict response to treatment.
    • May not be indicted for patients with genotypes 2/3.
  • Quantitative Virus Detection Tests
    • Genotype 1:
      • A change in viral level is used to monitor response to hepatitis C treatment.
      • Test before treatment starts
      • Test at 12 weeks